Boehringer Ingelheim Corporation Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*

Published: Jan 26, 2012

INGELHEIM, Germany--(BUSINESS WIRE)--FOR NON-US MEDIA ONLY

Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate afatinib* in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.

Back to news